Steady-state serum concentrations of olanzapine in patients subjected to antipsychotic treatment;Serummonitorering af olanzapin under antipsykotisk behandling

Ugeskrift for Laeger

Volumn 162, Issue 36, 2000, Pages 4802-4805

  Linnet, Kristian ^a   Olesen, Ole Vendelin ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; MAJOR CLINICAL STUDY; PSYCHOPHARMACOLOGY; PSYCHOSIS;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG MONITORING; HUMANS; PIRENZEPINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0034605092     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bredkjær SR, Gerlach J. Olanzapin. Et nyt antipsykotikum. Ugeskr Læger 1997; 159: 7160-4.
2. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37: 177-93.
3. Marder SR, Davis JM, Janicak PG. Use and interpretation of neuroleptic plasma levels. I: Marder SR, Davis JM, Janicak PG, eds. Clinical use of neuroleptic plasma levels. Washington, DC: American Psychiatric Press Inc. 1993: 137-42.
4. Bolvig-Hansen L, Larsen NE. Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology 1985; 87: 16-9.
5. Landmark J, Bengtsson F, Nordin C, Reis M, Wålinder J. Therapeutic drug monitoring of the SSRIs citalopram, paroxetine and sertraline in the treatment of depression in the elderly reduces drug costs. I: Balant LP, Benitez J, Dahl SG, Gram LF, Pinder RM, Potter WZ, eds. Clinical pharmacology in psychiatry: finding the right dose of psychotropic drugs. Cost B1 medicine. Luxembourg: Office for Official Publications of the European Communities, 1998: 133-42.
6. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication. Ther Drug Monit 1999; 21: 87-90.
7. Olesen OV, Linnet K. Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J Chromatogr Biomed Sci Appl 1998; 714: 309-15.
8. Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B 1995; 668: 85-90.
9. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical responsein acutely ill schizophrenic patients. J Clin Psychopharmacol 1997; 17: 472-7.
10. Aravagiri M, Ames D, Wirshing WC, Marder SR. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther Drug Monit 1997; 19: 307-13.
11. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155: 921-8.
12. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996; 276: 658-66.
13. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992, 13: 1561-8.
14. Licht RW, Olesen OV, Friis P, Laursen T. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine [letter]. J Clin Psychopharmacol 2000; 20: 110-2 .
15. Callaghan JT, Cerimele BJ, Kassahun KJ, Nyhart EH, Hoyes-Beehler PJ. Kondraske GV. Olanzapine: interaction study with imipramine. J Clin Pharmacol 1997; 37: 971-8.
16. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996; 41: 181-6.